ANTARES PHARMA, INC.

(ATRS)
 SummaryQuotesChartsNewsRatingsCompany 
Quotes 5-day view   End-of-day quote. End-of-day quote Nasdaq
05/17/2022 05/18/2022 05/19/2022 05/20/2022 05/23/2022 Date
5.58 5.58 5.58 5.59 5.59 Last
1414387 1352175 2613524 1763417 2707496 Volume
+0.18% 0.00% 0.00% +0.18% 0.00% Change
Company
Antares Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. The Company develops, manufactures, and commercializes, for itself or with partners, therapeutic products using its drug delivery systems. The Company products include XYOSTED... 
More about the company
Ratings of Antares Pharma, Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
-
More Ratings
All news about ANTARES PHARMA, INC.
05/24ANTARES PHARMA, INC. : Entry into a Material Definitive Agreement, Termination of a Materi..
AQ
05/24Antares Pharma, Inc. Announces Management Changes
CI
05/24ANTARES PHARMA, INC.(NASDAQCM : ATRS) dropped from NASDAQ Composite Index
CI
05/24ANTARES PHARMA, INC.(NASDAQCM : ATRS) dropped from S&P Pharmaceuticals Select Industry Ind..
CI
05/24ANTARES PHARMA, INC.(NASDAQCM : ATRS) dropped from S&P Global BMI Index
CI
05/24ANTARES PHARMA, INC.(NASDAQCM : ATRS) dropped from S&P TMI Index
CI
05/12Halozyme Says Antitrust Act Waiting Period Expires for Antares Pharma Acquisition
MT
05/10ANTARES PHARMA, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND R..
AQ
05/10Antares Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 202..
CI
05/05ANTARES PHARMA INVESTOR ALERT BY THE : Kahn Swick & Foti, LLC Investigates Adequacy of Pri..
BU
04/26Halozyme Therapeutics Launches Cash Tender Offer to Acquire Antares Pharma Shares
MT
04/25ANTARES PHARMA INVESTOR ALERT BY THE : Kahn Swick & Foti, LLC Investigates Adequacy of Pri..
BU
04/14Ladenburg Thalmann Downgrades Antares Pharma to Neutral From Buy
MT
04/14HC Wainwright Downgrades Antares Pharma to Neutral From Buy; Price Target is $5.60
MT
04/14Piper Sandler Downgrades Antares Pharma to Neutral From Overweight, Adjusts Price Targe..
MT
More news
News in other languages on ANTARES PHARMA, INC.
05/24Antares Pharma, Inc. annonce des changements de direction
05/12Halozyme déclare que la période d'attente de la loi antitrust a expiré pour l'acquisiti..
05/10Antares Pharma, Inc. annonce ses résultats pour le premier trimestre se terminant le 31..
04/26Halozyme Therapeutics propose une offre publique d'achat en espèces pour acquérir les a..
04/13MISE À JOUR SECTORIELLE : Les actions du secteur de la santé enregistrent des gains modest..
More news
Analyst Recommendations on ANTARES PHARMA, INC.
More recommendations
Chart ANTARES PHARMA, INC.
Duration : Period :
Antares Pharma, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Managers and Directors
Patrick Madsen Senior Vice President-Operations
Helen I. Torley Director
Nicole LaBrosse Director
Tram Bui Vice President-Communications & Investor Relations
Peter L. Sadowski SVP-Technology Portfolio & Intellectual Property
Sector and Competitors
1st jan.Capi. (M$)
ANTARES PHARMA, INC.56.58%955
ABBOTT LABORATORIES-22.23%191 641
MEDTRONIC PLC-12.79%119 876
BECTON, DICKINSON AND COMPANY2.10%71 528
BAXTER INTERNATIONAL INC.-22.20%33 626
HOYA CORPORATION-29.46%31 948